Device Trial Radar · NCT07620626
Real-World Study of Woven EndoBridge for Intracranial Aneurysm Treatment
Last checked: Nov 20, 2026Latest source record: Jun 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,000
Planned (sponsor's estimate)
Start
Jun 10, 2026
Primary completion
Jun 30, 2028
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Xuanwu Hospital, BeijingAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Shenzhen Second People's Hospital; ZhuHai Hospital; Third Affiliated Hospital, Sun Yat-Sen University; First Affiliated Hospital, Sun Yat-Sen University; Guangdong Provincial People's Hospital; Guangdong Second Provincial General Hospital; Zhujiang Hospital; Nanfang Hospital, Southern Medical University; The First Medical Center of Chinese PLA General Hospital; Beijing Chao Yang Hospital; Beijing Tiantan Hospital; Zhongnan Hospital; Tongji Hospital; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Huashan Hospital; Fudan University; RenJi Hospital; Ruijin Hospital; Henan Provincial People's Hospital; The First Affiliated Hospital of Zhengzhou University; Nanyang Central Hospital; First Affiliated Hospital Xi'an Jiaotong University; The First Affiliated Hospital of Air Force Medical University; The Second Affiliated Hospital of Air Force Military Medical University; Sichuan Provincial People's Hospital; West China Hospital; The First Affiliated Hospital of Anhui Medical University; First Affiliated Hospital of Harbin Medical University; The Second Affiliated Hospital of Harbin Medical University; Xiangya Hospital of Central South University; The Second Xiangya Hospital, Central South University; The First Hospital of Jilin University; Second Hospital of Jilin University; Nanjing Gulou Hospital; First Hospital of China Medical University; Qilu Hospital of Shandong University; First Affiliated Hospital of Chongqing Medical University; People's Hospital of Guangxi Zhuang Autonomous Region; The Affiliated Hospital Of Guizhou Medical University; First Affiliated Hospital of Fujian Medical University; MicroVention, Inc., a Terumo company; Anhui Provincial Hospital; Zhongshan Hospital of Hubei Province; Beijing Haidian Hospital; Peking University Third Hospital; Beijing Anzhen Hospital; Yichang Central People's Hospital; The General Hospital of Eastern Theater Command; The General Hospital of Northern Theater Command; Southwest Hospital, China; Guangxi Hospital of the First Affiliated Hospital, Sun Yat-sen University; Affiliated Hospital of Yunnan University; Second Affiliated Hospital, Zhejiang University, School of Medicine; Tangshan Worker's Hospital; The Affiliated Hospital of Qingdao University
- First posted
- Jun 2, 2026
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
We designed the Real-World Study of Woven EndoBridge for Intracranial Aneurysm Treatment (WEB-RWS), an ambidirectional, multicenter, post-market real-world study with a prospective active surveillance component. The study will include patients with IAs treated with commercially available WEB devices under the direction of treating physicians in routine clinical practice. Clinical, procedural, imaging, and safety data will be collected using a standardized electronic data capture system, with safety events adjudicated by an independent clinical events committee and imaging outcomes assessed by an independent core laboratory. The primary objective is to evaluate 12-month adequate aneurysm occlusion and major adverse events after WEB treatment. The study is expected to provide comprehensive post-market evidence on the real-world performance of the WEB device in China, including its safety, effectiveness, clinical appropriateness, and health economic value in routine neurointerventional practice.
Conditions
- Intracranial Aneurysm
Interventions
Intrasaccular Flow Disruption DeviceDevice
The intervention of interest is treatment of intracranial aneurysms using the commercially available MicroVention Woven EndoBridge device. The device is an intrasaccular flow disruption device used during endovascular treatment according to routine clinical practice and the approved instructions for use. Treatment decisions and procedural details are determined by the treating physician.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Major Adverse EventsTime frame: Up to 1 Year After the Index Procedure
- Proportion of Aneurysms With Adequate Occlusion Based on Raymond-Roy Occlusion ClassificationTime frame: 12 Months After the Index Procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xuanwu Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.